Prothena (PRTA) News Today

Prothena Co. plc (NASDAQ:PRTA - Free Report) - Analysts at Zacks Research raised their Q2 2025 earnings per share estimates for shares of Prothena in a research note issued on Tuesday, July 23rd. Zacks Research analyst E. Bagri now anticipates that the biotechnology company will earn ($1.48) per

SG Americas Securities LLC trimmed its holdings in shares of Prothena Co. plc (NASDAQ:PRTA - Free Report) by 87.7% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 16,720 shares of the biotechnology company's stock a

Prothena Co. plc (NASDAQ:PRTA - Get Free Report) was the recipient of a significant decline in short interest in June. As of June 30th, there was short interest totalling 5,100,000 shares, a decline of 23.4% from the June 15th total of 6,660,000 shares. Based on an average trading volume of 527,700 shares, the days-to-cover ratio is currently 9.7 days.

Prothena Co. plc (NASDAQ:PRTA - Free Report) - Leerink Partnrs boosted their Q2 2024 earnings per share estimates for Prothena in a research report issued on Tuesday, July 9th. Leerink Partnrs analyst R. Li now forecasts that the biotechnology company will post earnings per share of $0.32 for the

Prothena Co. plc (NASDAQ:PRTA - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the seven research firms that are covering the firm, Marketbeat reports. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company

Prothena (NASDAQ:PRTA) Share Price Crosses Below 200 Day Moving Average of $26.45

Royal Bank of Canada reiterated a "sector perform" rating and set a $28.00 target price on shares of Prothena in a research report on Wednesday.

Wellington Management Group LLP increased its position in shares of Prothena Co. plc (NASDAQ:PRTA - Free Report) by 21.1% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 2,594,102 shares of the biotechnology company's stoc

Prothena (NASDAQ:PRTA) Trading 4% Higher

Prothena Co. plc (NASDAQ:PRTA - Free Report) - Research analysts at Zacks Research upped their Q2 2024 earnings per share (EPS) estimates for Prothena in a research report issued on Tuesday, June 18th. Zacks Research analyst E. Bagri now forecasts that the biotechnology company will post earnings

Prothena (NASDAQ:PRTA) Stock Price Down 3.8%

Prothena (NASDAQ:PRTA) Sets New 1-Year Low at $19.44

Price T Rowe Associates Inc. MD raised its stake in Prothena Co. plc (NASDAQ:PRTA - Free Report) by 10.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,237,351 shares of the biotechnol

PFM Health Sciences LP reduced its holdings in Prothena Co. plc (NASDAQ:PRTA - Free Report) by 77.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 189,744 shares of the biotechnology company's stoc

First Light Asset Management LLC trimmed its stake in shares of Prothena Co. plc (NASDAQ:PRTA - Free Report) by 27.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,088,801 shares of the biotechn

Prothena (NASDAQ:PRTA) Shares Down 5%

Seven Eight Capital LP bought a new stake in shares of Prothena Co. plc (NASDAQ:PRTA - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 56,946 shares of the biotechnology company's stock, value

Armistice Capital LLC bought a new position in shares of Prothena Co. plc (NASDAQ:PRTA - Free Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The fund bought 278,000 shares of the biotechnology company's stock, valued at approximately $10,103,000. Armistice Cap

Prothena (NASDAQ:PRTA) Trading Up 6.7%

Dimensional Fund Advisors LP lessened its holdings in Prothena Co. plc (NASDAQ:PRTA - Free Report) by 21.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 867,635 shares of the biotechnology company's stock after selli

Prothena Co. plc (NASDAQ:PRTA - Free Report) - Zacks Research lifted their Q2 2024 earnings estimates for Prothena in a report issued on Monday, May 27th. Zacks Research analyst E. Bagri now anticipates that the biotechnology company will post earnings per share of ($1.22) for the quarter, up fro

Prothena (NASDAQ:PRTA) Reaches New 52-Week Low at $19.52

Jump Financial LLC lowered its stake in Prothena Co. plc (NASDAQ:PRTA - Free Report) by 89.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 6,457 shares of the biotechnology company's stock after sellin

Prothena Co. plc (NASDAQ:PRTA - Free Report) - Stock analysts at Leerink Partnrs lowered their FY2028 earnings per share estimates for Prothena in a research note issued to investors on Wednesday, May 8th. Leerink Partnrs analyst R. Li now expects that the biotechnology company will post earnings

HC Wainwright reduced their target price on Prothena from $90.00 to $84.00 and set a "buy" rating on the stock in a report on Thursday.

Prothena (NASDAQ:PRTA - Get Free Report) issued its quarterly earnings data on Wednesday. The biotechnology company reported ($1.34) earnings per share for the quarter, missing analysts' consensus estimates of ($1.21) by ($0.13). Prothena had a negative net margin of 160.91% and a negative return on equity of 24.84%. During the same period last year, the business posted ($0.89) EPS.

Prothena (NASDAQ:PRTA) will be releasing earnings after the market closes on Wednesday, May 8, Zacks reports.

Prothena (NASDAQ:PRTA) Hits New 12-Month Low at $20.32

Prothena (NASDAQ:PRTA) Sets New 1-Year Low at $21.31

Prothena Co. plc (NASDAQ:PRTA - Free Report) - Stock analysts at Leerink Partnrs lowered their Q1 2024 EPS estimates for shares of Prothena in a report issued on Tuesday, April 9th. Leerink Partnrs analyst R. Li now forecasts that the biotechnology company will post earnings per share of ($1.14)